The partnership will harness both FJB and Iontas' proprietary antibody libraries and technology platforms to investigate novel therapeutic targets for autoimmune and inflammatory diseases.
Pandion focuses on the development of innovative modular therapeutics using its TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform.
The TALON effector modules are based on immunomodulatory molecules that act as regulatory control points within the immune system.
In conjunction with a tissue-specific targeting moiety, the effectors create novel bifunctional molecules for the treatment of autoimmune and inflammatory diseases.
Under the terms of the agreement, Pandion will access the novel libraries and platform technologies provided by FJB and Iontas.
A dedicated FJB/ Iontas FTE will be assigned to the project with the aim of discovering diverse panels of novel target binders for use within the TALON platform.
The agreement extends an existing relationship between the companies and gives Pandion the option to use standard phage display or mammalian display as the engines for the discovery of next generation antibodies.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial